Bicara Therapeutics (BCAX) Net Income towards Common Stockholders (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$56.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 52.56% year-over-year to -$56.2 million; the trailing twelve-month figure through Mar 2026 stood at -$157.3 million (down 70.38% YoY), and the FY2025 full-year result was -$138.0 million, down 102.88% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$56.2 million, down from -$37.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$12.4 million in Q4 2023 and bottomed at -$56.2 million in Q1 2026.
• The 4-year median for Net Income towards Common Stockholders is -$22.8 million (2023), against an average of -$27.0 million.
• The widest annual swing landed in 2024, when Net Income towards Common Stockholders increased 23.48%; it then tumbled 194.58% in 2025.
• A 4-year view of Net Income towards Common Stockholders shows it stood at -$12.4 million in 2023, then plunged by 68.46% to -$21.0 million in 2024, then tumbled by 78.39% to -$37.4 million in 2025, then sank by 50.35% to -$56.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$56.2 million (Q1 2026), -$37.4 million (Q4 2025), and -$36.3 million (Q3 2025), per Business Quant data.

Peer Comparison